Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1638 1656 1799
This examiner grants 64% of resolved cases
John David Moore is an examiner in Tech Center 1700 and Art Unit 1638. He has 53 resolved cases, resulting in an allowance rate of 64.2 percent. This 64.2 percent rate suggests a generally favorable outcome for many applicants. The median days to allowance is 1275.
The interview lift for this examiner is 24.8 percent. This 24.8 percent lift indicates that interviews are an effective method for moving cases toward allowance. When compared to the 64.2 percent allowance rate, the 24.8 percent lift shows that direct engagement provides a clear advantage. Practitioners should factor the 1275-day median pendency into their planning for Art Unit 1638.
With 53 resolved cases, the examiner's data provides a reliable baseline for applicants. The 64.2 percent allowance rate and the 1275-day timeline are key indicators of his prosecution style. The 24.8 percent interview lift is an important tactical consideration for any applicant seeking to navigate the 1275-day process efficiently.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18304472 | GENE THERAPEUTICS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | Final Rejection | University of Massachusetts |
| 18683697 | TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18472847 | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF HUMAN CELLULAR IMMUNE SYSTEM | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18241669 | METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY | Final Rejection | Sanofi |
| 18858543 | METHOD FOR CONVERTING HUMAN SOMATIC CELLS INTO PROLIFERATIVE NEURAL STEM CELLS | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18800933 | SUSPENSION-BASED 3D CULTURE METHOD FOR ORGANOIDS | Non-Final OA | BRIGHAM YOUNG UNIVERSITY |
| 17930810 | ADAPTATION OF PLATFORM HOSTS TO IGF- MEDIA | Non-Final OA | Amgen Inc. |
| 18800672 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 17704539 | WOUND TREATMENTS AND METHODS OF STABILIZING, PROTECTING, AND TREATING A WOUND | Non-Final OA | Coloplast A/S |
| 18711287 | RNA SEQUENCES THAT INDUCE FLUORESCENCE OF SMALL MOLECULE FLUOROPHORES, MOLECULAR COMPLEXES, SENSORS, AND METHODS OF USE THEREOF | Non-Final OA | CORNELL UNIVERSITY |
| 18695720 | METHOD FOR PRODUCING T CELL | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18552165 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | Non-Final OA | TRANSLATE BIO, INC. |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | Non-Final OA | Sana Biotechnology, Inc. |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | Non-Final OA | Sana Biotechnology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy